GO
Loading...

MS, Citi Settle on Morgan Stanley Smith Barney Price Without Third Party

Tuesday, 11 Sep 2012 | 11:53 AM ET

After a third party valuation of their joint venture, Morgan Stanley Smith Barney, came in below $14 billion, Citigroup and Morgan Stanley negotiated a deal that values the unit at $13.5 billion and provides a road map for Morgan Stanley to acquire 100 percent of the firm by June of 2015 based on that value.

The two firms had turned to the firm of Perella Weinberg to determine a value for MSSB when they were unable to do so on their own.

Faber Report: MS, Citi Reach Agreement
CNBC's David Faber reports the details on Morgan Stanley's deal to acquire a 14 percent stake of MSSB from Citi.

Citi has been carrying the value of the joint venture at $23.3 billion, while Morgan Stanley believed the firm’s "fully distributed trading price" was worth $9.5 billion as of June 1, 2012 (as per their agreement). (Read More: Morgan Stanley's $4 Billion Week.)

In the end, Morgan’s value was closer to where Perella came in, but because its determination was not in the middle third of their two values (between $14 billion and $18.2 billion), the two banks were not obligated to use that value. Instead they embarked on their own negotiations that stretched through last evening and wound up with Tuesday’s deal.

While Citi will be forced to record a write-down (as it previously warned was possible), it has the certainty of receiving proceeds of $6.61 billion for its 49 percent stake in the asset between now and June of 2015. Citi expects to record a non-cash GAAP charge to net income of approximately $2.9 billion after-tax in the third quarter, according to Reuters. (Read More: The World's Safest Banks.)

Morgan Stanley, which paid $2.7 billion to Citi when the merger of the two firms took place in 2009, also has the certainty of knowing what it will pay to take full control.

—By CNBC's David Faber
@DavidFaberCNBC

  Price   Change %Change
C
---
MS
---

Featured

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • CNBC's David Faber and Carl Icahn, chairman, Icahn Enterprises, discuss corporate boards, a dysfunctional system, his impact as an activist investor and why what he does is important, as well as the use of poison pills to fend off activists. He also finds himself in the unusual position of defending Bill Ackman's recent efforts to partner with Valeant and acquire Allergan.

  • Discussing new technology in the Permian, growing market in North America, and higher earnings, with Dave Lesar, Halliburton chairman, president and CEO.

  • Paul Raines, GameStop CEO, discusses how its leadership in digital sales, market share, and ability to drive loyalty with rewards propels consumers to stay with the gaming store.